Obexelimab
Experimental drug
From Wikipedia, the free encyclopedia
Obexelimab is an experimental drug developed to treat IgG4-related disease and lupus. It works as a "bifunctional, non-cytolytic, humanised monoclonal antibody that binds CD19 and Fc gamma receptor IIb to inhibit B cells, plasmablasts, and CD19-expressing plasma cells."[1][2]
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Target | CD19 and Fc gamma receptor IIb |
| Clinical data | |
| Other names | AMG 729 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
